| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3324 | Methylhonokiol | Novel Class of Cannabinoid CB2 Receptor Inverse Agonist |
|
| DCC3325 | Methylnaltrexone Iodide | Peripherally restricted μ-opioid antagonist |
|
| DCC3326 | Met-in-3s | Highly Selective Class II MET Inhibitor |
|
| DCC3327 | Metoclopramide Hydrochloride | Dopamine D2 antagonist, antiemetic |
|
| DCC3328 | Metocurine | Non-depolarizing muscle relaxant |
|
| DCC3329 | Metrizoate Calcium | Radiographic Contrast Agent |
|
| DCC3330 | Mfn103 | Novel Dual Fluorescent and Magnetic Resonance False Neurotransmitter |
|
| DCC3331 | Mg2-1812 | Novel potent negative allosteric modulator (NAM) of mGlu2 |
|
| DCC3332 | Mg-277 | Novel potent inhibitor of the p53-MDM2 interaction with an IC50 value of 67.5 nmol/L, against acute leukemia cell lines with different p53 status and was much less effective in inducing MDM2 degradation |
|
| DC3333 | mG2N001 Featured | mG2N001 is a potent negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) with IC50 of 93 nM. |
|
| DCC3334 | Mgcd516 | Novel, multi-targeted kinase inhibitor, demonstrating potent inhibition of Trk, RET and DDR, in addition to Met, Axl and VEGFRs |
|
| DCC3335 | Mgs-0028 | Selective metabotropic glutamate 2/3 receptor agonist |
|
| DCC3336 | Mgs-0039 | Potent and orally active group II mGluR antagonist with antidepressant-like potential |
|
| DCC3337 | Mhi-148 | Near-infrared cyanine dye, acting as an optical imaging agent |
|
| DCC3338 | Mhi-i2 | Novel photodynamic antitumor agent |
|
| DCC3339 | mhy1556 | Novel tyrosinase inhibitor, showing concentration-dependent inhibitory effects with no significant cytotoxicity in cell viability assay |
|
| DCC3340 | mhy218 | Novel potent HDAC inhibitor, possessing potent anticancer activities |
|
| DCC3341 | Mhy219 | Novel potent histone deacetylase (HDAC) inhibitor, inducing apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells |
|
| DCC3342 | mhy336 | Novel topoisomerase II inhibitor, markedly inducing apoptotic cell death via the mitochondria-mediated intrinsic pathway in LNCaP cells |
|
| DCC3343 | mhy384 | Novel tyrosinase inhibitor, down-regulating of MITF and tyrosinase through direct tyrosinase inhibition |
|
| DCC3344 | mhy407 | Novel sensitizer of cancer cells, significantly increasing DNA damage as determined by DNA breakage, levels of damage-responsive proteins, and DNA foci |
|
| DCC3345 | Mhy-449 | Novel inducer of G2/M phase arrest in the cell cycle progression, resulting in growth inhibition and induction of apoptosis in a concentration-dependent manner, and inhibition of proliferation in a time-dependent manner |
|
| DCC3346 | mhy498 | Novel inhibitor of nitric oxide-induced melanogenesis, targeting the NO-induced cGMP signaling pathway |
|
| DCC3347 | mhy-794 | Novel tyrosinase inhibitor, directly inhibiting mushroom tyrosinase |
|
| DCC3348 | Mhy884 | Novel tyrosinase inhibitor, suppressing UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress |
|
| DCC3349 | Mi-1061 | Novel Chemically Stable, Potent, and Efficacious MDM2 Inhibitor |
|
| DCC3350 | Mi-1900 | Novel inhibitor of TMPRSS2, also strongly preventing SARS-CoV-2 multiplication and CPE in Calu-3 cells in a dose-dependent manner. causing strong inhibition of SARS-CoV-2 replication |
|
| DCC3351 | Mi-319 | Novel MDM2 antagonist, restoring p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
|
| DCC3352 | Mi-432 | Novel matriptase-1/matriptase-2 (MT-1/2) inhibitor, also inhibiting TMPRSS2, proteolytic activation and multiplication of influenza A virus in Calu-3 cells |
|
| DCC3353 | mi-888 Tfa Salt | Highly Potent and Efficacious MDM2 Inhibitor |
|
